当前位置: 首页 >> 检索结果
1. Degarelix Versus Goserelin Plus Bicalutamide in the Short-Term Relief of Lower Urinary Tract Symptoms in Prostate Cancer Patients: Results of a Pooled Analysis.
作者: Malcolm Mason.;Pierre Richaud.;Zsolt Bosnyak.;Anders Malmberg.;Anders Neijber.
来源: Low Urin Tract Symptoms. 2017年9卷2期82-88页
In patients with prostate cancer (PCa), prostate enlargement may give rise to lower urinary tract symptoms (LUTS); many patients suffer from moderate-to-severe symptoms. We compare the efficacy of degarelix and goserelin plus bicalutamide in improving LUTS in PCa patients.
2. Eastern Cooperative Oncology Group and American College of Radiology Imaging Network Randomized Phase 2 Trial of Neoadjuvant Preoperative Paclitaxel/Cisplatin/Radiation Therapy (RT) or Irinotecan/Cisplatin/RT in Esophageal Adenocarcinoma: Long-Term Outcome and Implications for Trial Design.
作者: Lawrence R Kleinberg.;Paul J Catalano.;Arlene A Forastiere.;Steven M Keller.;Edith P Mitchel.;Pramila Rani Anne.;Al B Benson.
来源: Int J Radiat Oncol Biol Phys. 2016年94卷4期738-46页
Toxicity, pathologic complete response, and long-term outcomes are reported for the neoadjuvant therapies assessed in a randomized phase 2 Eastern Cooperative Oncology Group and American College of Radiology Imaging Network trial for operable esophageal adenocarcinoma, staged as II-IVa by endoscopy/ultrasonography (EUS).
3. Efficacy of second-line erlotinib in patients postprogression of first-line chemotherapy in head and neck cancers.
作者: V Patil.;A Karpe.;V Noronha.;A Joshi.;V Muddu.;A Bhattacharjee.;S Dhumal.;K Prabhash.
来源: Indian J Cancer. 2015年52卷4期629-31页
Oral tyrosine kinase inhibitor (gefitinib and erlotinib) have been used in the palliative treatment of head and neck cancers with limited success. In this report, we aim to quantify the symptomatic benefit, progression-free survival (PFS) and overall survival (OS) when erlotinib is given as second-line treatment in Head and neck cancers.
4. A Prospective Comparison of the Effects of Interfractional Variations on Proton Therapy and Intensity Modulated Radiation Therapy for Prostate Cancer.
作者: Maryam Moteabbed.;Alexei Trofimov.;Gregory C Sharp.;Yi Wang.;Anthony L Zietman.;Jason A Efstathiou.;Hsiao-Ming Lu.
来源: Int J Radiat Oncol Biol Phys. 2016年95卷1期444-453页
To quantify and compare the impact of interfractional setup and anatomic variations on proton therapy (PT) and intensity modulated radiation therapy (IMRT) for prostate cancer.
5. Role of neo-adjuvant chemotherapy in locally advanced breast cancer.
Locally advanced breast cancer (LABC) is common in developing countries. The advancement of disease leads to decreased probability of radical cure and increase in treatment cost. The study evaluated neo adjuvant chemotherapy with MRM and MRM followed by adjuvant chemotherapy and also the effectiveness of neo-adjuvant chemotherapy in down staging advanced disease and offering radical cure.
6. Prospective randomized trial to compare accelerated (six fractions a week) radiotherapy against concurrent chemoradiotherapy (using conventional fractionation) in locally advanced head and neck cancers.
作者: Manoj Gupta.;Rohit Mahajan.;Vikrant Kaushal.;Rajeev K Seem.;Manish Gupta.;Tapesh Bhattacharyya.
来源: J Cancer Res Ther. 2015年11卷4期723-9页
Concurrent chemoradiation (CCRT) is currently considered to be the standard of care in locally advanced head and neck cancer. The optimum radiotherapy schedule for best local control and acceptable toxicity is not yet clear. We aimed at shortening of treatment time by using accelerated radiation, thereby comparing the disease response, loco-regional tumor control and tolerability of accelerated radiation (six fractions per week) against CCRT in locally advanced head and neck cancer.
7. Is thyroid gland an organ at risk in breast cancer patients treated with locoregional radiotherapy? Results of a pilot study.
作者: Mutahir Ali Tunio.;Mushabbab Al Asiri.;Yasser Bayoumi.;Laura G Stanciu.;Naji Al Johani.;Eyad Fawzi Al Saeed.
来源: J Cancer Res Ther. 2015年11卷4期684-9页
Aim was to evaluate the dose distribution within the thyroid gland its association with hypothyroidism in breast cancer (BC) patients receiving supraclavicular (SC) radiation therapy (RT).
8. Role of Surgical Versus Clinical Staging in Chemoradiated FIGO Stage IIB-IVA Cervical Cancer Patients-Acute Toxicity and Treatment Quality of the Uterus-11 Multicenter Phase III Intergroup Trial of the German Radiation Oncology Group and the Gynecologic Cancer Group.
作者: Simone Marnitz.;Peter Martus.;Christhardt Köhler.;Carmen Stromberger.;Elke Asse.;Peter Mallmann.;Heinz Schmidberger.;Renato José Affonso Júnior.;João Soares Nunes.;Jalid Sehouli.;Volker Budach.
来源: Int J Radiat Oncol Biol Phys. 2016年94卷2期243-53页
The Uterus-11 trial was designed to evaluate the role of surgical staging in patients with cervical cancer before primary chemoradiation therapy (CRT). The present report provides the toxicity data stratified by the treatment arm and technique.
9. Phenytoin mouthwash to treat cancer therapy-induced oral mucositis: A pilot studyPrimary neuroendocrine carcinoma of breast: A rare tumor.
作者: M Baharvand.;M Hamian.;M A Moosavizadeh.;A Mortazavi.;A Ameri.
来源: Indian J Cancer. 2015年52卷1期81-5页
Oral mucositis is one of the most common side effects of cancer therapy with no definite treatment. Phenytoin has positive effects on healing of mucosal and dermal wounds. In this study efficacy of 1% phenytoin mouthwash on severity of mucositis (on the basis of WHO scale), pain relief (based on Visual Analogue Scale), and improvement of patients' quality of life (on the basis of EORTC-QLQ-H and N35 questionnaire) was evaluated.
10. Study Design and Rationale for a Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Selumetinib in Combination With Docetaxel as Second-Line Treatment in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer (SELECT-1).
Oncogenic KRAS mutations represent the largest genomically defined subset of lung cancer, and are associated with activation of the RAS/RAF/MEK/ERK pathway. There are currently no therapies specifically approved for patients with KRAS-mutant (KRASm) non-small-cell lung cancer (NSCLC), and these patients derive less clinical benefit from chemotherapy than the overall NSCLC population. In a recent phase II study, selumetinib (AZD6244, ARRY-142886), an oral, potent and selective, allosteric MEK1/2 inhibitor with a short half-life, combined with docetaxel, improved clinical outcome as second-line treatment for patients with KRASm NSCLC. This combination will be further evaluated in the phase III SELECT-1 study.
11. [Phase II clinical trial of two different modes of administration of the induction chemotherapy for locally advanced nasopharyngeal carcinoma].
作者: Ting Bi.;Feng Jin.;Weili Wu.;Jinhua Long.;Yuanyuan Li.;Xiuyun Gong.;Xiuling Luo.;Zhuoling Li.;Qianyong He.;Bo Qu.
来源: Zhonghua Zhong Liu Za Zhi. 2015年37卷9期676-81页
To compare the therapeutic effects, toxic side effects and influence on the immune function in patients treated with TPF [docetaxel (DOC) + cisplatin (DDP) + 5-fluorouracil (5-Fu)] induction chronochemotherapy and conventional chemotherapy for locally advanced nasopharyngeal (NPC).
12. First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results From a Randomized Phase III Trial.
作者: Mark Boye.;Xin Wang.;Vichien Srimuninnimit.;Jin Hyoung Kang.;Chun-Ming Tsai.;Mauro Orlando.;Tarun Puri.;Jong Seok Kim.;Narayan Rajan.;James Chih-Hsin Yang.
来源: Clin Lung Cancer. 2016年17卷2期150-60页
The efficacy results from an open-label, randomized, multicenter study found no significant difference in progression-free survival between pemetrexed plus cisplatin followed by maintenance gefitinib (PC/G) and gefitinib monotherapy (G) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) and unknown epidermal growth factor receptor (EGFR) mutation status (hazard ratio favored PC/G). The present report describes the quality of life (QoL) results from that trial.
13. Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer.
作者: Hideki Kusagaya.;Naoki Inui.;Masato Karayama.;Tomoyuki Fujisawa.;Noriyuki Enomoto.;Shigeki Kuroishi.;Yutaro Nakamura.;Hiroyuki Matsuda.;Koshi Yokomura.;Naoki Koshimizu.;Mikio Toyoshima.;Shiro Imokawa.;Takashi Yamada.;Toshihiro Shirai.;Hiroshi Hayakawa.;Takafumi Suda.
来源: Lung Cancer. 2015年90卷3期410-6页
Although antiemetic management has improved, better control of chemotherapy-induced nausea and vomiting (CINV), particularly during the delayed phase, is needed. The benefit of combination therapy using dexamethasone and the second-generation 5-hydroxytryptamine-3 receptor antagonist palonosetron compared with that of other such receptor antagonists in carboplatin-based chemotherapy is unclear. The effectiveness of adding aprepitant for CINV treatment in moderate emetogenic chemotherapy is also unknown. We compared the efficacy and safety of triple antiemetic therapy using aprepitant, palonosetron, and dexamethasone with that of double antiemetic therapy using palonosetron and dexamethasone in patients with advanced non-small-cell lung cancer receiving carboplatin-containing chemotherapy.
14. A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer.
作者: Gerald Schmid-Bindert.;Walburga Engel-Riedel.;Martin Reck.;Wolfgang Schuette.;Jan Stöhlmacher.;Jürgen R Fischer.;Julien Mazières.;Christos Chouaid.;Martin Wolf.;Nuria Vinolas.;Victoria Soldatenkova.;Veronique Ripoche.;Tuan Nguyen.;Carla Visseren-Grul.
来源: Lung Cancer. 2015年90卷3期397-404页
We investigated the feasibility of cisplatin or carboplatin combined with pemetrexed as adjuvant treatment in patients with completely resected Stage IB/II Non-Small-Cell Lung Cancer (NSCLC).
15. One year treatment of Barrett's oesophagus with proton pump inhibitors (a multi-center study).
作者: Z Babic.;Z Bogdanovic.;Z Dorosulic.;Z Petrovic.;M Kujundzic.;M Banic.;M Marusic.;R Heinzl.;B Bilić.;M Andabak.
来源: Acta Clin Belg. 2015年70卷6期408-13页
Aim of the study was to investigate the effects of 1-year therapy by different proton pump inhibitors (PPIs) on epithelial tissue and surrounding inflammatory changes in Barrett's oesophagus, in patients who have abandoned invasive therapy.
16. A Randomized Multicenter Phase III Study of Single Administration of Mecapegfilgrastim (HHPG-19K), a Pegfilgrastim Biosimilar, for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC).
作者: Caicun Zhou.;Yunchao Huang.;Donglin Wang.;Changshan An.;Fuxiang Zhou.;Yali Li.;Gongyan Chen.;Changping Wu.;Jianxing He.;Gang Wu.;Xia Song.;Jianfei Gao.;Wei Liu.;Baolan Li.;Jianhua Shi.;Cheng Huang.;Jingrui Yu.;Jueping Feng.;Hongmei Yue.;Meiqi Shi.;Jielai Xia.
来源: Clin Lung Cancer. 2016年17卷2期119-27页
Mecapegfilgrastim (code name HHPG-19K) is a biosimilar to pegylated recombinant human granulocyte-colony stimulating factor (PEG-rhG-CSF). The efficacy and safety of mecapegfilgrastim, using a regimen of once-per-cycle injection of 100-μg/kg or a fixed 6-mg dose, were evaluated for the prophylactic therapy for neutropenia in patients with advanced non-small-cell lung cancer (NSCLC) who were treated with myelosuppressive chemotherapy.
17. Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center.
作者: Vinayak Muralidhar.;Meredith M Regan.;Lillian Werner.;Mari Nakabayashi.;Carolyn P Evan.;Joaquim Bellmunt.;Toni K Choueiri.;Aymen A Elfiky.;Lauren C Harshman.;Rana R McKay.;Mark M Pomerantz.;Christopher J Sweeney.;Mary-Ellen Taplin.;Philip W Kantoff.;Paul L Nguyen.
来源: Clin Genitourin Cancer. 2016年14卷4期e299-305页
We evaluated the incidence and predictors of the use of long-term (2-3 years) versus shorter term androgen deprivation therapy (ADT) in radiation-managed men with high-risk prostate cancer.
19. Prospective comparative effectiveness trial for malignant bowel obstruction: SWOG S1316.20. PRODIGE 34-FFCD 1402-ADAGE: Adjuvant chemotherapy in elderly patients with resected stage III colon cancer: A randomized phase 3 trial.
作者: Thomas Aparicio.;Eric Francois.;Laurence Cristol-Dalstein.;Elisabeth Carola.;Emilie Maillard.;Elena Paillaud.;Frédérique Retornaz.;Roger Faroux.;Thierry André.;Laurent Bedenne.;Jean-François Seitz.
来源: Dig Liver Dis. 2016年48卷2期206-7页 |